Using Either Intravenous (IV) or Subcutaneous (SQ) Treprostinil to Treat Pulmonary Hypertension Related to Underlying Interstitial Lung Disease
Phase of Trial: Phase II
Latest Information Update: 08 Mar 2018
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary hypertension
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 02 Mar 2018 Status changed from recruiting to completed.
- 21 Jul 2008 New trial record.